Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.58 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.57 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29557250 | 1.00 | SLC29A1 (0.58) | SLC29A1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL28403790 | 0.88 | ADORA2A (0.58) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL6765506 | 0.86 | ADORA3 (0.49) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL2480941 | 0.81 | ADORA2A (0.62) | ADORA2AADORA2B | |
| SCHEMBL6474053 | 0.80 | SLC29A1 (0.68) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL6474066 | 0.80 | SLC29A1 (0.68) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL31307310 | 0.80 | SLC29A1 (0.67) | SLC29A1ADORA2AADORA2B | |
| SCHEMBL155837 | 0.80 | SLC29A1 (0.75) | SLC29A1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL28477260 | 0.80 | ADORA2A (0.67) | SLC29A1ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL155836 | 0.80 | SLC29A1 (0.75) | SLC29A1ADORA2AADORA2BADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1524 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240366793-A1 | MAMMALIAN POLYCISTRONIC EXPRESSION SYSTEM FOR DIRECT TRANSLATION FROM RNA AND SECRETION OF CARGO | CALIFORNIA INST OF TECHN (US) | 2024-11-07 | — | — | US | claimed |
| US-20240229075-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-07-11 | — | — | US | claimed |
| WO-2024129779-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| EP-4379052-A2 | MRNA PURIFICATION BY TANGENTIAL FLOW FILTRATION | Ethris GmbH (DE) | 2024-06-05 | — | — | EP | claimed |
| US-20240102065-A1 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | CureVac SE (DE) | 2024-03-28 | — | — | US | claimed |
| EP-4334446-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | CureVac SE (DE) | 2024-03-13 | — | — | EP | claimed |
| WO-2024031087-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | MODERNATX, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| EP-4306643-A2 | PLASMID CONTAINING A SEQUENCE ENCODING AN MRNA WITH A SEGMENTED POLY(A) TAIL | ethris GmbH (DE) | 2024-01-17 | — | — | EP | claimed |
| WO-2023215498-A2 | COMPOSITIONS AND METHODS FOR CD28 ANTAGONISM | MODERNATX, INC. (US) | 2023-11-09 | — | — | WO | claimed |
| EP-4087938-A2 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | CureVac AG (DE) | 2022-11-16 | — | — | EP | claimed |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2022-09-22 | — | — | US | claimed |
| WO-2022162027-A2 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | CUREVAC AG (DE) | 2022-08-04 | — | — | WO | claimed |
| EP-4013880-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CureVac AG (DE) | 2022-06-22 | — | — | EP | claimed |
| WO-2021028439-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | CUREVAC AG (DE) | 2021-02-18 | — | — | WO | claimed |
| EP-4746905-A1 | RSV VACCINE | Astrazeneca AB (SE) | 2026-05-27 | — | — | EP | disclosed |
| US-12636304-B2 | — | — | 2026-05-26 | — | — | US | disclosed |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | BRISTOL MYERS SQUIBB CO (US) | 2026-05-21 | — | — | US | disclosed |
| US-20130115272-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-09 | — | — | US | disclosed |
| WO-2013052523-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-04-11 | — | — | WO | disclosed |
| US-20120156251-A1 | CATIONIC OIL-IN-WATER EMULSIONS | GLAXOSMITHKLINE BIOLOGICALS SA (BE) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636304-B2 | — | RNMT, RNGTT, NSUN2 | SLC29A1 390/4885ADORA2A 494/4885ADORA2B 758/4885 |
| US-20260138999-A1 | REAGENTS AND THEIR USE FOR MODULAR ENANTIODIVERGENT SYNTHESIS OF C-P BONDS | RNGTT, CDA, DCTD | SLC29A1 203/4885ADORA2A 276/4885ADORA2B 218/4885 |
| US-20240229075-A1 | IMPROVED NUCLEIC ACID SEQUENCE FOR CELL TYPE SPECIFIC EXPRESSION | NSUN3, NSUN2, RNASE1 | SLC29A1 413/4885ADORA2A 1751/4885ADORA2B 1206/4885 |
| US-20240102065-A1 | METHOD OF REDUCING THE IMMUNOSTIMULATORY PROPERTIES OF IN VITRO TRANSCRIBED RNA | RNGTT, POLRMT, POLR2H | SLC29A1 1232/4885ADORA2A 1134/4885ADORA2B 660/4885 |
| US-20220296628-A1 | RNA COMBINATIONS AND COMPOSITIONS WITH DECREASED IMMUNOSTIMULATORY PROPERTIES | TLR3, EIF2AK2, STING1 | SLC29A1 3073/4885ADORA2A 337/4885ADORA2B 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.